Seeking Alpha
 

Sequenom, Inc. (SQNM)

- NASDAQ
  • Nov. 7, 2013, 4:12 PM
    • Sequenom (SQNM) Q3: EPS of -$0.19, beats by $0.03.
    • Revenue of $44M (+26% Y/Y), beats by $3.4M. (PR)
    | Comment!
  • Oct. 31, 2013, 12:45 PM
    | Comment!
  • Oct. 31, 2013, 10:57 AM
    • Sequenom (SQNM -11.3%) falls hard on news the U.S. District Court for the Northern District of California has invalidated a patent related to fetal cell-free DNA detection.
    • Ultimately, the court ruled in favor of Ariosa Diagnostics in finding that the patent sought to cover a natural phenomenon.
    | Comment!
  • Oct. 18, 2013, 5:46 PM
    • Top Gainers, as of 5:15 p.m.: SQNM +2.5%. AFSI +2.4%. VNDA +2.2%. CE +1.5%. VJET +1.4%.
    • Top Losers, as of 5:15 p.m: DQ -6.6%. JAH -2.4%. SIX -2.0%. UVXY -2.0%. PENN -1.8%.
    | Comment!
  • Sep. 23, 2013, 4:27 PM
    • Sequenom (SQNM) hires Jefferies to assist in the evaluation of strategic alternatives for SQNM's Genetic Analysis unit. (PR)
    • For H1, revenues for the business fell 3% Y/Y while sales for the Sequenom CMM diagnostics services segment grew 316%. (PR)
    | 2 Comments
  • Aug. 21, 2013, 5:37 PM
    | Comment!
  • Aug. 19, 2013, 5:26 PM
    • Sequenom (SQNM) is planning to reduce its workforce by up to 75 employees as part of "an overall cost reduction effort," the company said in a regulatory filing. (8-K
    • SQNM says the move will save it $10M in compensation-related expenses on an annualized basis.
    • The company also says it plans to book ~$1.2M in severance-related expenses in Q3.
    | Comment!
  • Aug. 16, 2013, 11:24 AM
    • Shares of Sequenom (SQNM +0.3%) pare losses to trade briefly in positive territory on chatter about a Wedbush note which purportedly says competitors Natera and Ariosa have received letters from the NY Department of Health regarding test processing.
    | 2 Comments
  • Aug. 9, 2013, 12:05 PM
    • Sequenom (SQNM +5%) pops on chatter that the company will be allowed to pursue a ban of a certain pre-natal test.
    | 1 Comment
  • Aug. 5, 2013, 7:44 AM
    • The New York Department of Health's Wadsworth Center Clinical Laboratory Evaluation Program issues a laboratory permit clearing the way for Sequenom (SQNM) to begin providing the state's healthcare professionals with the MaterniT21 PLUS test.
    • In other company news, SQNM's North Carolina lab gets accreditation from the College of American Pathologists. (PR)
    • Shares +3% premarket.
    | Comment!
  • Aug. 1, 2013, 8:54 AM
    • CombiMatrix (CBMX) and Sequenom (SQNM) enter into an agreement to collaborate on the promotion and marketing of "chromosomal microarray analysis testing services to broaden and confirm the results of noninvasive, prenatal testing."
    • The companies will provide physicians with "technical training" and plan to offer "counseling, education and support services to [both] physicians and their patients."
    • CBMX +15% , SQNM +1.33% premarket. (PR)
    | Comment!
  • Jul. 25, 2013, 9:15 AM
    Premarket gainers: FB +31%. BIDU +18%. TQNT +14%. TRIP +14%. LOGI +13%. OKE +10%. MEET +9%. CDTI +9%. BSX +9%. IMAX +8%. SPR +7%. FFIV +7%. UA +7%. YNDX +6%. ZNGA +6%. RENN +5%.
    Losers: SQNM -36%. CROX -24%. PHM -7%. SI -7%. WDC -5%.
    | Comment!
  • Jul. 25, 2013, 9:08 AM
    Better late than never: William Blair, Lazard, and Ladenburg Thalmann all downgrade shares of Sequenom (SQNM) on the heels of Wednesday's Q2 report. The stock is now off 36% premarket. (Previous: Payment concerns tank SQNM; Q2 results)
    | 3 Comments
  • Jul. 25, 2013, 7:58 AM
    Shares of Sequenom (SQNM) are down 32% premarket following Wednesday evening's Q2 report. Investors are nervous about comments the company made regarding delays in test payments. For more, see the Q&A on the conference call, notably the back and forth between management and Jefferies' Brandon Couillard. (transcript)
    | Comment!
  • Jul. 24, 2013, 5:53 PM
    After-hours top gainers, as of 5:15 p.m.: FB +19%. TRIP +15%. BIDU +13%. XOOM +12%. TQNT +11%.
    After-hours top losers: SQNM -33%. CROX -21%. EQIX -8%. RT -7%. VAR -6%.
    | 2 Comments
  • Jul. 24, 2013, 4:25 PM
    More on Sequenom's (SQNM) Q2: CMM diagnostics services revenues come in at $24.5M. The company says it (as well as competitors) "experienced delays in receipt of payments as a result of molecular diagnostics coding changes adopted by CMS, Medicaid and third party payors." Total tests accessioned rise 130% to 46,700 patient samples (38K MaterniT21 PLUS samples). Overall gross margin climbs 200 bps Y/Y. CFO Paul Maier says he is "disappointed by the delay in the collection of diagnostic segment revenues during the second quarter," but notes that collections should improve in H2. Update 4:39: Shares slide 25% AH. (PR)
    | Comment!
SQNM vs. ETF Alternatives
Company Description
Sequenom Inc is a molecular diagnostic testing and genetics analysis company which provides molecular diagnostic testing services.
Sector: Healthcare
Industry: Biotechnology
Country: United States